Study guide
10.1 Routine Antenatal Care, Screening & Fetal Assessment
CAMC Regional Medical Registration Examination Part 1 MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Registration Framework & Test Strategy
1.1 Exam Format, Administration & Caribbean Medical Registration Pathways 1.2 Clinical Reasoning & Single-Best-Answer MCQ Test-Taking Strategy 1.3 Regional Epidemiology & Caribbean Healthcare Context
2 Chapter 2: Internal Medicine: Cardiovascular Disorders
2.1 Acute Coronary Syndromes & Myocardial Infarction Management 2.2 Heart Failure Syndromes & Cardiogenic Shock 2.3 Cardiac Arrhythmias, Conduction Blocks & BLS/ACLS Algorithms 2.4 Valvular Heart Disease, Infective Endocarditis & Hypertension
3 Chapter 3: Internal Medicine: Respiratory Medicine & Critical Care
3.1 Asthma & Chronic Obstructive Pulmonary Disease Exacerbations 3.2 Community-Acquired Pneumonia, Hospital-Acquired Pneumonia & Tuberculosis 3.3 Pulmonary Embolism, Pleural Effusion & Pneumothorax
4 Chapter 4: Internal Medicine: Endocrinology & Metabolic Disorders
4.1 Diabetes Mellitus, Diabetic Ketoacidosis & Hyperosmolar Hyperglycaemic State 4.2 Thyroid Disorders: Thyrotoxicosis, Hypothyroidism & Thyroid Storm 4.3 Adrenal Disorders, Pituitary Pathology & Calcium Homeostasis
5 Chapter 5: Internal Medicine: Gastroenterology, Hepatology & Nephrology
5.1 Upper & Lower Gastrointestinal Bleeding: Evaluation & Management 5.2 Cirrhosis, Portal Hypertension & Hepatic Encephalopathy 5.3 Acute Kidney Injury & Chronic Kidney Disease Staging 5.4 Fluid, Electrolyte & Acid-Base Emergencies
6 Chapter 6: Internal Medicine: Neurology, Haematology & Infectious Diseases
6.1 Stroke, Transient Ischaemic Attack & Acute Neurological Deficits 6.2 Sickle Cell Disease, Haemoglobinopathies & Transfusion Medicine 6.3 Dengue Fever, Arboviral Infections & Leptospirosis 6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship
7 Chapter 7: General Surgery: Acute Abdomen & Surgical Emergencies
7.1 Acute Abdomen: Peritonitis, Appendicitis & Acute Cholecystitis 7.2 Intestinal Obstruction, Bowel Ischaemia & Perforated Viscus 7.3 Abdominal Wall Hernias: Inguinal, Femoral, Umbilical & Strangulation 7.4 Upper & Lower GI Surgical Pathology & Postoperative Complications
8 Chapter 8: General Surgery: Trauma Resuscitation, Shock & Critical Care
8.1 ATLS Primary Survey & Hemorrhagic Shock Resuscitation 8.2 Thoracic Trauma: Tension Pneumothorax, Hemothorax & Flail Chest 8.3 Abdominal & Pelvic Trauma: FAST Examination & Damage Control Surgery 8.4 Traumatic Brain Injury, Burns & Wound Management
9 Chapter 9: General Surgery: Surgical Subspecialties & Perioperative Care
9.1 Urological Emergencies: Acute Retention, Renal Colic, Torsion & Hematuria 9.2 Musculoskeletal Trauma: Fractures, Dislocations & Compartment Syndrome 9.3 Preoperative Assessment, Surgical Site Infections & Fluid Management 9.4 Otolaryngology: Ear, Nose, Throat & Upper Airway Emergencies 9.5 Clinical Ophthalmology: Acute Red Eye, Glaucoma & Retinal Emergencies
10 Chapter 10: Obstetrics: Antenatal Care, Labor & Complications
10.1 Routine Antenatal Care, Screening & Fetal Assessment 10.2 Hypertensive Disorders of Pregnancy: Pre-eclampsia & Eclampsia 10.3 Antepartum Haemorrhage: Placenta Praevia & Placental Abruption 10.4 Normal Labor, Labor Dystocia & Obstetric Analgesia
11 Chapter 11: Obstetrics & Gynaecology: Postpartum & Pathology
11.1 Postpartum Haemorrhage, Normal Puerperium Physiology & Postpartum Care 11.2 Ectopic Pregnancy, Miscarriage & Gestational Trophoblastic Disease 11.3 Abnormal Uterine Bleeding & Pelvic Inflammatory Disease 11.4 Contraception, Cervical Cancer Screening & Gynaecological Malignancies 11.5 Obstetric & Gynaecological Instruments & Cervical Specimen Collection (PAP Smear Procedures)
12 Chapter 12: Paediatric Medicine: Neonatal Care, Growth & Nutrition
12.1 Neonatal Resuscitation, APGAR Scoring & Prematurity Complications 12.2 Neonatal Jaundice: Physiological, Pathological & Kernicterus 12.3 Growth Monitoring, Developmental Milestones & Failure to Thrive 12.4 Protein-Energy Malnutrition: Kwashiorkor, Marasmus & Nutritional Deficiencies
13 Chapter 13: Paediatric Medicine: Common Illnesses & Emergencies
13.1 Acute Gastroenteritis, Dehydration Assessment & WHO ORS Protocols 13.2 Paediatric Respiratory Illness: Croup, Bronchiolitis & Asthma 13.3 Childhood Infections, Exanthems & Caribbean Immunisation Schedules 13.4 Paediatric Surgical & Medical Emergencies: Intussusception & Febrile Seizures 13.5 Social Paediatrics, Child Protection & Vulnerable Child Health
14 Chapter 14: Psychiatry: Clinical Assessment & Psychopharmacology
14.1 Depressive Disorders, Bipolar Affective Disorder & Suicide Risk Assessment 14.2 Psychosis, Schizophrenia & Acute Delirium vs Dementia 14.3 Anxiety Disorders, Substance Misuse & Psychotropic Side Effects
15 Chapter 15: Community Health, Epidemiology & Preventive Medicine
15.1 Epidemiological Study Designs, Measures of Association & Bias 15.2 Screening Test Performance: Sensitivity, Specificity, PPV & NPV 15.3 Outbreak Investigation, Levels of Prevention & Caribbean NCD Control
16 Chapter 16: Internal Medicine: Rheumatology, Connective Tissue & Dermatology
16.1 Connective Tissue & Collagen Vascular Diseases 16.2 Bone & Joint Diseases: Non-Traumatic Arthropathies & Metabolic Bone Disorders 16.3 Clinical Dermatology: Common, Inflammatory, Bullous, Malignant & Drug-Induced Dermatoses
17 Chapter 17: Anaesthetics, Intensive Care & Clinical Measurements
17.1 Important Anaesthetic Techniques, Airway Management & Methods of Administration 17.2 Clinical Measurements & Intensive Care Monitoring: Cardiac Output, Arterial Blood Gases & Pulmonary Functions 17.3 Acute Pain Management, Multimodal Analgesia & Critical Care Sedation
10.1 Routine Antenatal Care, Screening & Fetal Assessment
Key Takeaways Explain This Topic AI
Routine antenatal booking mandates a comprehensive laboratory panel—including ABO/Rh typing with red cell antibody screen, CBC, hemoglobin electrophoresis for sickle hemoglobinopathies, rubella IgG, syphilis VDRL/RPR, opt-out HIV, HBsAg, and midstream urine culture—to identify treatable maternal-fetal hazards early in gestation.
Gestational diabetes mellitus (GDM) is diagnosed between 24 and 28 weeks of gestation via a 75 g 2-hour oral glucose tolerance test (OGTT) using IADPSG/WHO cutoffs (fasting 5.1–6.9 mmol/L, 1-hour >= 10.0 mmol/L, or 2-hour 8.5–11.0 mmol/L); fasting >= 7.0 or 2-hour >= 11.1 mmol/L indicates overt diabetes in pregnancy; failure of lifestyle modification necessitates metformin or basal-bolus insulin therapy.
Discrepancies between symphysiofundal height (SFH) and gestational age (> 2 to 3 cm) mandate formal biometric ultrasound to differentiate fetal growth restriction (FGR) or oligohydramnios from macrosomia or polyhydramnios.
The biophysical profile (BPP) systematically evaluates five biophysical parameters (NST, fetal breathing movements, gross body movements, fetal tone, and a single deepest vertical amniotic fluid pocket >= 2 cm); scores <= 4/10 indicate chronic fetal asphyxia demanding urgent delivery consideration.
Umbilical artery Doppler velocimetry is the definitive hemodynamic surveillance tool in placental insufficiency, progressing from elevated systolic/diastolic ratios to absent and reversed end-diastolic flow (AEDF/REDF), with REDF indicating severe placental insufficiency requiring admission, intensified surveillance and gestation-dependent delivery planning.
Last updated: November 2026
Routine Antenatal Care & The Caribbean Healthcare Framework
Routine antenatal care (ANC) serves as the primary clinical vehicle for risk stratification, early detection of maternal-fetal pathology, nutritional optimization, and birth preparedness. While the World Health Organization (WHO) 2016 model recommends a minimum of eight antenatal contacts—scheduled at booking (< 12 weeks), 20, 26, 30, 34, 36, 38, and 40 weeks—many regional primary healthcare networks across the English-speaking Caribbean combine this framework with the traditional visit schedule (every 4 weeks until 28 weeks, every 2 weeks until 36 weeks, and weekly thereafter until delivery).
The initial booking visit establishes baseline clinical parameters, validates gestational age, and stratifies obstetric risk:
Accurate Gestational Dating : Accurate determination of the expected date of delivery (EDD) is essential. While Naegele's rule calculates the EDD by adding 7 days and 9 months (or 1 year minus 3 months) to the first day of the last normal menstrual period (LNMP), early first-trimester ultrasonography measuring crown-rump length (CRL, accurate to within +/- 5 to 7 days between 7 and 13+6 weeks) represents the definitive diagnostic gold standard.
Baseline Maternal Hemodynamics & Anthropometry : Baseline blood pressure measurement before 20 weeks is critical to differentiate preexisting chronic hypertension from pregnancy-induced hypertensive disorders. Body mass index (BMI) calculation guides gestational weight gain targets and identifies patients requiring early metabolic surveillance.
Social, Medical, and Obstetric History : Systematic documentation of previous cesarean sections, uterine surgery, recurrent miscarriages, prior preterm birth, history of postpartum hemorrhage, and chronic maternal conditions (cardiac disease, renal impairment, epilepsy, hemoglobinopathies).
First-Trimester Booking Investigations & Hemoglobinopathy Screening
A standardized laboratory panel must be performed at the initial antenatal visit to screen for asymptomatic infections, hematological disorders, and maternal alloimmunization risks:
ABO and Rhesus (RhD) Typing & Antibody Screen
Maternal blood grouping and indirect Coombs testing (red cell antibody screen) must be performed at booking. In non-sensitized RhD-negative women carrying an RhD-positive fetus, transplacental fetomaternal hemorrhage can trigger maternal anti-D IgG alloantibody production. These IgG antibodies cross the placenta in subsequent pregnancies, causing fetal hemolytic disease of the fetus and newborn (HDFN), severe fetal anemia, erythroblastosis fetalis, and hydrops fetalis.
Prophylaxis : Routine antenatal anti-D immunoglobulin prophylaxis (RAADP) is administered at 28 weeks of gestation as a single dose of 1,500 IU (300 mcg) or split into two doses (at 28 and 34 weeks). A further 1,500 IU dose is given within 72 hours of delivery if the infant is confirmed to be RhD-positive.
Sensitizing Events : Assess bleeding, pregnancy loss, ectopic pregnancy, invasive testing, abdominal trauma and external cephalic version promptly. Give anti-D within 72 hours when indicated, using the gestation- and event-specific local protocol, particularly in early pregnancy. At or beyond 20 weeks, quantify fetomaternal hemorrhage with a Kleihauer-Betke test or flow cytometry to guide additional doses; do not delay the initial dose for the result.
Sensitized Patients : If maternal anti-D titers are elevated (>= 1:16 or >= 1:32), anti-D immunoglobulin is ineffective. Management requires serial maternal antibody titration and middle cerebral artery (MCA) Doppler peak systolic velocity (PSV) surveillance; MCA-PSV > 1.5 multiples of the median (MoM) suggests significant fetal anemia and prompts fetal-medicine assessment, usually fetal blood sampling with preparation for intrauterine transfusion if anemia is confirmed and delivery is not safer.
Complete Blood Count & Hemoglobinopathy Evaluation
Physiological plasma volume expansion (40% to 50%) exceeds the increase in red cell mass (20% to 30%), resulting in physiological "hemodilution anemia." The WHO defines anemia in pregnancy as:
- First Trimester : Hemoglobin < 11.0 g/dL (Hematocrit < 33%)
- Second Trimester : Hemoglobin < 10.5 g/dL (Hematocrit < 32%)
- Third Trimester : Hemoglobin < 11.0 g/dL (Hematocrit < 33%)
Nutritional iron deficiency anemia is characterized by microcytic, hypochromic red cells with serum ferritin < 30 mcg/L. However, across the Caribbean population, high frequencies of sickle cell disease (HbSS, HbSC, HbS-beta-thalassemia) and alpha/beta-thalassemia traits mandate routine hemoglobin electrophoresis (or HPLC) at the booking visit. Women with sickle cell trait (HbAS) require continuous monitoring for asymptomatic bacteriuria and urinary tract infections. Mothers with homozygous sickle cell disease (HbSS) face extreme risks of acute chest syndrome, vaso-occlusive bone crises, placental infarction, severe fetal growth restriction, and pre-eclampsia, requiring coordinated maternal-fetal subspecialist care, supplemental folic acid (5 mg daily), and avoidance of dehydration and cold exposure.
Infectious Disease & Asymptomatic Bacteriuria Screening
Syphilis Serology : Universal screening with non-treponemal tests (VDRL or RPR) confirmed by treponemal testing (TPHA or FTA-ABS). Untreated maternal syphilis leads to congenital syphilis, spontaneous abortion, non-immune hydrops, stillbirth, and neonatal skeletal/neurological defects. Intramuscular Benzathine Penicillin G (2.4 million units IM single dose for primary/secondary/early latent; weekly for 3 consecutive weeks for late latent or unknown duration) is the only proven therapy that prevents vertical transmission; penicillin-allergic gravidas must undergo hospital desensitization.
HIV Universal Opt-Out Screening : Early identification enables combination antiretroviral therapy (cART) that suppresses maternal plasma viral load to undetectable levels (< 50 copies/mL), reducing vertical transmission rates from > 25% to < 0.5%. Cesarean section is indicated if viral load exceeds 1,000 copies/mL at 36 weeks.
Hepatitis B Surface Antigen (HBsAg) : Identifies chronic maternal carrier status. Neonates born to HBsAg-positive mothers must receive both the Hepatitis B vaccine and Hepatitis B immune globulin (HBIG 0.5 mL IM) at separate anatomical sites within 12 hours of birth, followed by completion of the vaccine series, achieving > 95% protection against perinatal transmission.
Rubella IgG Immunity : Live-attenuated MMR vaccine is strictly contraindicated during pregnancy due to theoretical teratogenicity. Non-immune women (rubella IgG negative) must avoid contact with rash illnesses and receive postpartum MMR vaccination prior to discharge, with advice to avoid pregnancy for at least 4 weeks.
Asymptomatic Bacteriuria (ASB) : High levels of progesterone cause smooth muscle relaxation, ureteral dilatation, and urinary stasis. A midstream clean-catch urine culture is mandatory at booking (diagnostic threshold: >= 10^5 CFU/mL of a single uropathogen, most commonly Escherichia coli ). Untreated ASB progresses to acute maternal pyelonephritis in up to 30% to 40% of cases, triggering preterm labor, sepsis, and low birth weight. Treatment requires a 3 to 7-day course of pregnancy-safe oral antimicrobials (nitrofurantoin [avoid in G6PD deficiency and at term], amoxicillin-clavulanate, or cephalexin), followed by a repeat test-of-cure culture.
Gestational Diabetes Mellitus: Screening, Diagnosis & Glycemic Control
Gestational diabetes mellitus (GDM) is hyperglycemia first detected during pregnancy that is below the diagnostic range for overt diabetes in pregnancy. Human placental lactogen (hPL), progesterone, cortisol, and placental growth hormone exert potent anti-insulinogenic effects that peak during the late second trimester (24 to 28 weeks).
Universal Screening & Diagnostic Criteria
Universal screening is conducted between 24 and 28 weeks of gestation using the 75 g 2-hour Oral Glucose Tolerance Test (OGTT) after an 8 to 14-hour overnight fast. High-risk women (pre-pregnancy BMI >= 30 kg/m², prior macrosomic neonate >= 4.0 kg, history of GDM, polycystic ovary syndrome, or strong first-degree family history of type 2 diabetes) undergo early 75 g OGTT testing at booking; if negative, testing is repeated at 24 to 28 weeks.
Under the internationally validated International Association of Diabetes and Pregnancy Study Groups (IADPSG) and WHO criteria, GDM is diagnosed if one or more plasma glucose values meet or exceed the following thresholds on the 75 g OGTT:
- Fasting Plasma Glucose (FPG) : 5.1 to 6.9 mmol/L (92 to 125 mg/dL)
- 1-Hour Plasma Glucose : >= 10.0 mmol/L (180 mg/dL)
2-Hour Plasma Glucose : 8.5 to 11.0 mmol/L (153 to 199 mg/dL). Fasting glucose >= 7.0 mmol/L or 2-hour glucose >= 11.1 mmol/L instead meets the diabetes-in-pregnancy range and requires prompt specialist management.
Maternal-Fetal Morbidity
Maternal glucose readily traverses the placenta via facilitated diffusion (GLUT transporters), whereas maternal insulin does not cross. Uncontrolled maternal hyperglycemia drives fetal pancreatic beta-cell hyperplasia and secondary hyperinsulinism (the Pedersen hypothesis). Insulin functions as a potent fetal anabolic growth hormone, yielding:
Fetal Macrosomia & Asymmetric Overgrowth : Disproportionate deposition of adipose tissue around the fetal shoulders and abdomen (abdominal circumference > 90th percentile), predisposing to severe shoulder dystocia, clavicular fracture, and brachial plexus avulsion (Erb-Duchenne palsy).
Neonatal Metabolic Collapse : Immediate post-delivery neonatal hypoglycemia resulting from abruptly severed maternal glucose supply in the presence of autonomous fetal hyperinsulinism.
Respiratory Distress Syndrome (RDS) : Elevated fetal insulin levels directly inhibit cortisol-mediated fibroblast-pneumocyte factor production, arresting pulmonary surfactant synthesis in type II pneumocytes despite biological term maturity.
Polycythemia & Hyperbilirubinemia : Fetal tissue hypoxia drives erythropoietin secretion, causing severe neonatal polycythemia (hematocrit > 65%), microvascular sludging, and hyperbilirubinemia.
Hypertrophic Cardiomyopathy : Transient hypertrophy of the interventricular septum, potentially obstructing the left ventricular outflow tract.
Therapeutic Protocols & Glycemic Targets
First-line therapy consists of Medical Nutrition Therapy (MNT) with a registered dietitian, structuring complex carbohydrates across three main meals and two to three snacks, combined with 30 minutes of daily moderate-intensity walking. Capillary blood glucose is monitored four times daily (fasting and 1 or 2 hours postprandially). The target glycemic levels are:
- Fasting Plasma Glucose : < 5.3 mmol/L (95 mg/dL)
- 1-Hour Postprandial : < 7.8 mmol/L (140 mg/dL)
- 2-Hour Postprandial : < 6.7 mmol/L (120 mg/dL)
If lifestyle modifications fail to maintain target glucose levels within 1 to 2 weeks (>= 20% of readings above target), pharmacological therapy is indicated. Metformin (500 mg orally once or twice daily, titrated up to 2,000 mg daily) is widely utilized as an effective oral agent. If metformin is insufficient, contraindicated, or if marked fetal abdominal circumference overgrowth is evident on ultrasound, subcutaneous insulin is initiated (neutral protamine Hagedorn [NPH] or detemir as basal insulin; regular human insulin or rapid-acting insulin aspart/lispro as preprandial boluses).
- Clinical & Biophysical Fetal Surveillance
- Symphysiofundal Height (SFH)
Symphysiofundal height measurement remains the primary clinical screening tool for fetal growth abnormalities in resource-conscious health settings. Using a non-elastic tape measure, distance is recorded along the midline of the maternal abdomen from the superior margin of the pubic symphysis to the uppermost palpable border of the uterine fundus, with the metric markings placed facedown to avoid examiner bias. Between 20 and 36 weeks of gestation, the SFH in centimeters corresponds to gestational age in weeks within +/- 2 to 3 cm:
SFH > 2 to 3 cm Below Dates : Suggests fetal growth restriction (FGR), oligohydramnios, transverse fetal lie, or mistaken dating.
SFH > 2 to 3 cm Above Dates : Suggests fetal macrosomia, polyhydramnios, multiple pregnancy, pelvic masses (leiomyoma), or mistaken dating.
Any significant SFH discrepancy warrants urgent formal ultrasound biometry measuring biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC), and femur length (FL) to derive the Estimated Fetal Weight (EFW).
Cardiotocography / Non-Stress Test (NST)
The Non-Stress Test monitors fetal heart rate (FHR) acceleration in response to spontaneous fetal movement, reflecting an intact, non-acidotic autonomic nervous system. Over a standard 20-minute window, criteria are:
Reactive (Normal) : Presence of >= 2 accelerations peaking at least 15 bpm above baseline and lasting >= 15 seconds from baseline to return (the "15 x 15 rule" for >= 32 weeks; for 28 to 32 weeks, "10 x 10" is accepted), with normal baseline rate (110 to 160 bpm) and moderate variability (6 to 25 bpm).
Non-Reactive : Fewer than 2 accelerations over 20 minutes. The tracing is immediately extended to 40 minutes to account for the physiological fetal sleep cycle (fetal quiet sleep typically lasts 20 to 40 minutes). Persistent non-reactivity requires progression to formal biophysical profile testing.
Biophysical Profile (BPP - Manning Score)
The Manning BPP integrates acute and chronic markers of fetal hypoxemia by combining ultrasound observation over 30 minutes with an external cardiotocograph. Each parameter receives 2 points if normal and 0 points if abnormal (maximum score: 10/10):
Non-Stress Test : Reactive tracing with >= 2 accelerations (+2).
Fetal Breathing Movements : At least one episode of continuous fetal breathing lasting >= 30 seconds (+2).
Gross Body Movements : At least three discrete body or limb movements (+2).
Fetal Tone : At least one episode of active limb/spine extension with prompt return to flexion, or opening and closing of a fetal hand (+2).
Amniotic Fluid Volume : Single deepest vertical pocket (DVP) of fluid >= 2 cm free of umbilical cord loops (+2). (Amniotic Fluid Index [AFI] 5 to 25 cm is also used).
Biophysical activities develop sequentially in embryonic life and are extinguished in reverse order under progressive asphyxia: fetal tone arises first (at 8 weeks) and is the last to vanish in severe hypoxemia; fetal breathing appears at 21 weeks and disappears early under mild hypoxemia. Amniotic fluid volume reflects chronic uteroplacental perfusion: chronic hypoxemia redirects fetal cardiac output away from kidneys to the brain and heart, diminishing fetal urine production and producing oligohydramnios.
Score 8/10 or 10/10 with Normal Fluid : Reassuring. Oligohydramnios requires further assessment and possible delivery regardless of the total score.
Score 6/10 : Equivocal; repeat within 24 hours when preterm and otherwise stable; consider delivery at term or with additional concerns.
Score <= 4/10 : Abnormal and concerning for fetal compromise; obtain urgent specialist assessment. Delivery is usually indicated, but management before 32 weeks depends on repeat surveillance, gestational age and the clinical situation.
Umbilical Artery Doppler Velocimetry in Fetal Growth Restriction
Umbilical artery Doppler velocimetry measures resistance within the fetoplacental microcirculation. In a healthy placenta, low vascular resistance yields high continuous forward flow throughout diastole, reflected by a low systolic-to-diastolic (S/D) ratio and low pulsatility index (PI).
In placental insufficiency and fetal growth restriction (FGR), progressive microvascular obliteration of tertiary placental villi elevates downstream resistance, producing sequential hemodynamic deterioration:
Elevated Resistance : Decreased end-diastolic velocity yielding elevated S/D ratio and PI (> 95th percentile).
Absent End-Diastolic Flow (AEDF) : Absent diastolic flow indicates severe placental resistance. Increase Doppler surveillance to 2 to 3 times weekly and intensify CTG monitoring, often as an inpatient. If stable, plan delivery at 33 to 34 weeks; deliver earlier for deterioration.
Reversed End-Diastolic Flow (REDF) : Reversed diastolic flow indicates severe placental insufficiency and a high risk of fetal compromise. Admit to a specialist centre, give antenatal corticosteroids if preterm delivery is expected, and monitor CTG at least once or twice daily. If stable, delivery is generally planned at 30 to 32 weeks; abnormal fetal testing or maternal deterioration can require earlier birth. Give magnesium sulfate for neuroprotection when delivery before 32 weeks is likely. Cesarean delivery is usually appropriate with these major Doppler abnormalities, according to the full clinical picture.
Ductus Venosus Doppler : An absent or reversed a-wave is a late warning of fetal cardiovascular compromise. Specialist early-FGR protocols combine this with gestational age and computerized CTG to decide delivery; it is not an isolated universal hours-to-delivery rule.
Antenatal Routine Booking & Surveillance Protocols
Investigation / Modality Standard Timing Normal / Diagnostic Threshold Primary Clinical Rationale
ABO & RhD Typing Booking (< 12 weeks) Maternal RhD negative vs positive Identifies risk of Rh alloimmunization; guides anti-D prophylaxis at 28w & post-delivery
Red Cell Antibody Screen Booking & 28 weeks Negative indirect Coombs test Detects irregular atypical IgG antibodies (anti-D, anti-Kell, anti-c) causing hemolytic disease
Hemoglobin / CBC Booking & 28 weeks Hb >= 11.0 g/dL (1st & 3rd tri); >= 10.5 (2nd tri) Screens for nutritional anemia and physiological hemodilution
Hb Electrophoresis Booking Normal HbA pattern (HbAA) Screens for sickle cell trait (HbAS), sickle cell disease (HbSS/SC), and thalassemias
VDRL / RPR Syphilis Booking & 28–32 weeks Non-reactive (confirmed by TPHA) Prevents congenital syphilis; treated immediately with Benzathine Penicillin G
HIV Opt-Out Screen Booking & 3rd trimester Non-reactive Universal screening for PMTCT; cART initiation prevents vertical transmission
HBsAg Booking Negative / Non-reactive Prevents vertical hepatitis B; neonate receives vaccine + HBIG within 12 hours
Rubella IgG Booking Positive (IgG titer >= 10 IU/mL) Confirms maternal immunity; non-immune mothers receive postpartum MMR vaccine
Urine Culture Booking < 10^5 CFU/mL Screens for asymptomatic bacteriuria; prevents acute pyelonephritis and preterm labor
75 g 2h OGTT 24–28 weeks (or booking if high risk) Fasting < 5.1; 1h < 10.0; 2h < 8.5 mmol/L One abnormal value diagnoses GDM unless overt-diabetes criteria apply (fasting >= 7.0 or 2h >= 11.1 mmol/L)
Symphysiofundal Height Every visit from 20 to 36 weeks Corresponds to GA in weeks (+/- 2–3 cm) Low-cost bedside screening for fetal growth restriction vs macrosomia/polyhydramnios
Cardiotocograph (NST) As indicated (>= 28–32 weeks) Reactive: >= 2 accelerations (15 bpm x 15 s in 20 min) Reassures autonomic integrity and fetal oxygenation
Biophysical Profile High-risk surveillance Reassuring: 8/10 or 10/10 with normal fluid; 6/10 equivocal; <= 4/10 abnormal; assess oligohydramnios separately Comprehensive multi-parameter evaluation of acute and chronic fetal hypoxia
Umbilical Artery Doppler Fetal growth restriction Positive continuous end-diastolic flow Evaluates placental resistance; AEDF/REDF requires intensified surveillance and gestation-dependent delivery planning